IL319974A - Malonate and glycolate salts of EGFR inhibitor - Google Patents

Malonate and glycolate salts of EGFR inhibitor

Info

Publication number
IL319974A
IL319974A IL319974A IL31997425A IL319974A IL 319974 A IL319974 A IL 319974A IL 319974 A IL319974 A IL 319974A IL 31997425 A IL31997425 A IL 31997425A IL 319974 A IL319974 A IL 319974A
Authority
IL
Israel
Prior art keywords
malonate
egfr inhibitor
glycolate salts
glycolate
salts
Prior art date
Application number
IL319974A
Other languages
English (en)
Hebrew (he)
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of IL319974A publication Critical patent/IL319974A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/06—Glycolic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL319974A 2022-11-03 2023-11-02 Malonate and glycolate salts of EGFR inhibitor IL319974A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263422365P 2022-11-03 2022-11-03
US202363464133P 2023-05-04 2023-05-04
US202363591670P 2023-10-19 2023-10-19
PCT/US2023/078473 WO2024097848A1 (fr) 2022-11-03 2023-11-02 Sels de malonate et de glycolate d'un inhibiteur d'egfr

Publications (1)

Publication Number Publication Date
IL319974A true IL319974A (en) 2025-05-01

Family

ID=89164547

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319974A IL319974A (en) 2022-11-03 2023-11-02 Malonate and glycolate salts of EGFR inhibitor

Country Status (8)

Country Link
EP (1) EP4611902A1 (fr)
JP (1) JP2025538076A (fr)
KR (1) KR20250093563A (fr)
CN (1) CN120569380A (fr)
AU (1) AU2023372570A1 (fr)
IL (1) IL319974A (fr)
MX (1) MX2025004240A (fr)
WO (1) WO2024097848A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024233313A1 (fr) * 2023-05-05 2024-11-14 Oric Pharmaceuticals, Inc. Inhibiteur d'egfr pour le traitement de cancers comprenant des mutations atypiques de l'egfr
WO2026080372A1 (fr) * 2024-10-07 2026-04-16 Oric Pharmaceuticals, Inc. Traitement de cancers comprenant des mutations extracellulaires et transmembranaires d'egfr

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0408689B8 (pt) 2003-03-25 2021-05-25 Laboratoires Fournier S A derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor
PT3943491T (pt) 2019-03-19 2025-07-28 Voronoi Inc Derivado de heteroarilo, método para a produção do mesmo e composição farmacêutica que compreende o mesmo como componente eficaz

Also Published As

Publication number Publication date
JP2025538076A (ja) 2025-11-26
CN120569380A (zh) 2025-08-29
WO2024097848A1 (fr) 2024-05-10
AU2023372570A1 (en) 2025-04-17
EP4611902A1 (fr) 2025-09-10
KR20250093563A (ko) 2025-06-24
MX2025004240A (es) 2025-07-01

Similar Documents

Publication Publication Date Title
IL319974A (en) Malonate and glycolate salts of EGFR inhibitor
IL317847A (en) Salts of SOS1 inhibitors
CA3243183A1 (fr) Inhibiteurs d'oncoprotéines ras
IL285493A (en) Crystalline forms of rsk inhibitor
IL288522A (en) Inhibitor of egfr for cancer treatment
EP3912976A4 (fr) Sel d'un inhibiteur d'egfr, forme cristalline et procédé de préparation associé
SG11202010882XA (en) Salts of an fgfr inhibitor
EP4011881A4 (fr) Forme cristalline d'un inhibiteur d'atr et son utilisation
IL290033A (en) A mek inhibitor for the treatment of stroke
EP3755690A4 (fr) Inhibiteurs d'egfr et leurs procédés d'utilisation
PT4146348T (pt) Inibidores da quinase nek7
IL313735A (en) Salts and solid forms of Pajfer inhibitor and processes for their preparation
IL326879A (en) EGFR allosteric inhibitors and methods of using them
HUE068724T2 (hu) Transzglutaminázok inhibitorai
EP3986407A4 (fr) Inhibiteurs allostériques d'egfr et leurs procédés d'utilisation
IL315980A (en) EGFR inhibitors
CA3272686A1 (fr) Sels de malonate et de glycolate d'un inhibiteur d'egfr
SI4192813T1 (sl) Zaviralci transglutaminaz
EP3971175A4 (fr) Forme cristalline de composé quinazolinone et son procédé de préparation
PL4192812T3 (pl) Inhibitory transglutaminaz
CA3307775A1 (fr) Formes salines et formes solides d'un inhibiteur d'egfr
CA3265788A1 (fr) Inhibiteurs d'egfr et leurs utilisations
GB202203181D0 (en) Inhibitors of elF4A
CA3278918A1 (fr) Inhibiteurs de mptp
HK40081439A (en) Cyano-pyrimidine inhibitors of egfr/her2